Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 23 articles:
HTML format



Single Articles


    September 2021
  1. BAUMGART DC, Le Berre C
    Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
    N Engl J Med. 2021;385:1302-1315.
    PubMed    


  2. SANDBORN WJ, Feagan BG, D'Haens G, Wolf DC, et al
    Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
    N Engl J Med. 2021;385:1280-1291.
    PubMed     Abstract available


    August 2021
  3. SCHETT G, McInnes IB, Neurath MF
    Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs.
    N Engl J Med. 2021;385:628-639.
    PubMed    


    April 2021
  4. CHANG JT
    Pathophysiology of Inflammatory Bowel Diseases. Reply.
    N Engl J Med. 2021;384:1378.
    PubMed    


  5. MRAVEC B
    Pathophysiology of Inflammatory Bowel Diseases.
    N Engl J Med. 2021;384:1377-1378.
    PubMed    


  6. GAFFNEY P, Gaffney R
    Pathophysiology of Inflammatory Bowel Diseases.
    N Engl J Med. 2021;384:1377.
    PubMed    


  7. CHEN CJ, Hu H, Liao WT
    Pathophysiology of Inflammatory Bowel Diseases.
    N Engl J Med. 2021;384:1376-1377.
    PubMed    


    February 2021
  8. THOMAS AS, Ma W, Wang Y
    Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors.
    N Engl J Med. 2021;384:581-583.
    PubMed    


    December 2020
  9. CHANG JT
    Pathophysiology of Inflammatory Bowel Diseases.
    N Engl J Med. 2020;383:2652-2664.
    PubMed    


    August 2020
  10. VITEK L, Tiribelli C
    Bilirubin, Intestinal Integrity, the Microbiome, and Inflammation.
    N Engl J Med. 2020;383:684-686.
    PubMed    


    July 2020
  11. CHEN RY, Kung VL, Das S, Hossain MS, et al
    Duodenal Microbiota in Stunted Undernourished Children with Enteropathy.
    N Engl J Med. 2020;383:321-333.
    PubMed     Abstract available


    June 2020
  12. ESFAHANI K, Hudson M, Batist G
    Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.
    N Engl J Med. 2020;382:2374-2375.
    PubMed    


    April 2020
  13. HABERMAN R, Axelrad J, Chen A, Castillo R, et al
    Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
    N Engl J Med. 2020 Apr 29. doi: 10.1056/NEJMc2009567.
    PubMed    


    March 2020
  14. BOHOSSIAN HB, Lopes EW, Roller LA, Ananthakrishnan AN, et al
    Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools.
    N Engl J Med. 2020;382:1042-1052.
    PubMed    


    January 2020
  15. SANDS BE, Schreiber S, Lirio RA
    Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply.
    N Engl J Med. 2020;382:93-94.
    PubMed    


  16. O'CONNOR DB, Lahiff C
    Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    N Engl J Med. 2020;382:92-93.
    PubMed    


  17. BIEMANS VBC, Hoentjen F, Pierik MJ
    Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    N Engl J Med. 2020;382:92.
    PubMed    


  18. SANDS BE, Marano C
    Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply.
    N Engl J Med. 2020;382:91.
    PubMed    


  19. ROWAN CR, Boland K, Harewood GC
    Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    N Engl J Med. 2020;382:91.
    PubMed    


    September 2019
  20. FARRELL RJ
    Biologics beyond Anti-TNF Agents for Ulcerative Colitis - Efficacy, Safety, and Cost?
    N Engl J Med. 2019;381:1279-1281.
    PubMed    


  21. SANDS BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, et al
    Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    N Engl J Med. 2019;381:1215-1226.
    PubMed     Abstract available


  22. SANDS BE, Sandborn WJ, Panaccione R, O'Brien CD, et al
    Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    N Engl J Med. 2019;381:1201-1214.
    PubMed     Abstract available


  23. LAI AR, Sheu L, Gensler LS, McQuaid K, et al
    A Terminal Event.
    N Engl J Med. 2019;381:970-976.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: